# Hemab Therapeutics

> Clinical-stage biopharmaceutical company (Copenhagen, Denmark; Cambridge, Massachusetts)
> developing prophylactic monoclonal and bispecific antibody therapeutics for serious,
> underserved bleeding and thrombotic disorders. Hemab operates no public API: there is no
> developer portal, API reference, OpenAPI/AsyncAPI/GraphQL contract, SDK, MCP server, or
> webhook surface on any host it controls.

This file was GENERATED by API Evangelist from the public Hemab Therapeutics website and the
apis.yml profile in this repository. Hemab does not publish an llms.txt of its own — a probe of
https://www.hemab.com/llms.txt returned 404 on 2026-08-22.

## Company

- [Hemab Therapeutics](https://www.hemab.com/): Corporate site. Webflow-hosted marketing surface.
- [About Hemab](https://www.hemab.com/about-us): Company, research approach, leadership team, pipeline, careers.
- [Therapeutic focus](https://www.hemab.com/therapeutic-focus): Coagulation and bleeding disorders Hemab targets.
- [News and media hub](https://www.hemab.com/news-media-hub): Dated company news and scientific presentations.
- [Contact](https://www.hemab.com/contact-us): General and medical-affairs contact channels.

## Audiences

- [For patients and caregivers](https://www.hemab.com/for-patients-caregivers): Therapeutic focus, clinical trials, how to connect.
- [For healthcare providers](https://www.hemab.com/for-healthcare-providers): Research approach, pipeline, clinical trials, medical affairs contact.
- [Expanded access policy](https://www.hemab.com/expanded-access-policy): Policy on access to investigational products outside clinical trials.

## Therapeutic areas

Glanzmann Thrombasthenia; von Willebrand Disease; Factor VII deficiency; Bernard-Soulier
Syndrome; heavy menstrual bleeding associated with inherited bleeding disorders. Named clinical
candidates appearing in Hemab's own 2026 disclosures include sutacimig (HMB-001) and HMB-002.

## Legal

- [Privacy policy](https://www.hemab.com/privacy-policy)
- [Clinical trial privacy notice](https://www.hemab.com/clinical-trial-privacy-notice)
- [Terms and conditions](https://www.hemab.com/terms-conditions)

## Optional

- [Investor relations](https://ir.hemab.com): Press releases and financial disclosures. Hosted on a separate IR platform; API Evangelist probes of this host timed out on 2026-08-22 and it was not verified.
- [Careers](https://career.hitalento.com/hemab/): Third-party applicant tracking system (HiTalento).

## Machine-readable surface (measured 2026-08-22)

- No OpenAPI, Swagger, GraphQL SDL, AsyncAPI or Postman collection found on any Hemab host.
- /openapi.json, /openapi.yaml, /swagger.json, /v1/openapi.json, /api-docs, /api, /docs, /redoc, /graphql: all 404 on www.hemab.com.
- api.hemab.com, developer.hemab.com, docs.hemab.com: do not resolve in DNS.
- Every /.well-known/ path probed returned 404; see well-known/hemab-therapeutics-well-known.yml.
- No first-party packages on npm, PyPI or any other public registry.
- github.com/hemab-therapeutics exists but is empty (0 public repositories, no description) and was not attributed to the company.